Intra-Cellular Therapies
ITCI
$73.12
Share price
-1.20%
Change (1 day)
17.46%
Change (1 year)
Categories
Intra-Cellular Therapies (ITCI) Fails to deliver data
Key failure to deliver metrics for Intra-Cellular Therapies:
- Last SEC data release: 2024-03-28
- Last 15 days FTD volume: $0.11 M
- Last 3 months FTD volume: $2.02 M
- Last year FTD volume: $42.98 M
Failures to deliver for Intra-Cellular Therapies (ITCI) - 3 months history
Number of shares, 3 months chartBiweekly Failures to deliver volume for Intra-Cellular Therapies (ITCI) - since 2014
Volume in USD (price x number of shares), data since 2014Intra-Cellular Therapies (ITCI) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2024 | $2.02 M | -95.2% |
| 2023 | $42.15 M | 51.56% |
| 2022 | $27.81 M | 16.21% |
| 2021 | $23.93 M | 25.98% |
| 2020 | $18.99 M | -33.46% |
| 2019 | $28.54 M | 2213.17% |
| 2018 | $1.23 M | -95.97% |
| 2017 | $30.59 M | 29.42% |
| 2016 | $23.63 M | -65.91% |
| 2015 | $69.33 M | 104.09% |
| 2014 | $33.97 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Xencor XNCR | $0.11 M | $2.43 M | 🇺🇸 USA |
 MediciNova MNOV | $0 M | $0.02 M | 🇺🇸 USA |
 Curis CRIS | N/A | $1.02 M | 🇺🇸 USA |